Sep. 8 at 1:19 PM
Stifel reiterated
$ALKS Buy-
$42 and said, We continue to believe that
$ALKS has a compelling drug in '2680/alixorexton in NT1 (and potentially NT2/IH).
#WorldSleep2025
$TAK
Stifel added: As it relates to the World SLEEP presentation over the weekend, the results continue to show a compelling efficacy profile, with a large effect size (25+ minutes) on MWT that looks superior to what we saw for Takeda's [
$TAK ] compound (20 minutes) in ph3.
MWT is also far from the full story as patients are reporting significant benefits in quality-of-life, cognition and function; moreover, more granular
data on cataplexy make us less concerned that the primary analysis missed statistical significance. The nuance here that may continue to be debated though will be visual disturbances (in the AE table referred to as "blurred vision") which occurred in 7/24 high dose patients, probably a little more than expected. Only one patient discontinued due to an AE though, so it still seems generally benign.
